Inmune bio, inc. (INMB)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS

-2,070

-2,318

-3,066

-392

-1,901

-1,879

-1,539

-6,173

-2,846

Adjustments to reconcile net loss to net cash used in operating activities:
Net cash used in operating activities:
Stock-based compensation

681

1,172

974

974

974

954

979

5,605

2,461

Changes in operating assets and liabilities:
Research and development tax credit receivable

144

-385

110

237

13

267

61

101

54

Other tax receivable

-6

-28

1

-60

128

9

-20

-7

-55

Joint development cost receivable

-

0

49

-14

-16

-15

-2

10

98

Prepaid expenses

168

-24

-77

5

179

-32

-203

227

-18

Prepaid expenses - related party

-26

-92

-126

163

81

-111

65

-60

-51

Accounts payable and accrued liabilities

293

64

160

-202

-173

363

40

-37

60

Accounts payable and accrued liabilities - related parties

28

127

-169

229

-168

248

-24

36

-173

Deferred grant

300

-

-

-

300

-

-

-

-

Operating lease liability - related party

13

-

-

-

-

-

-

-

-

Net cash used in operating activities

-1,034

-433

-1,945

-1,617

-1,387

-462

-449

-817

-328

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock

1,002

0

0

4,957

7,251

0

0

0

900

Purchase of common stock

1,012

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-9

0

0

4,957

7,251

0

0

0

900

Impact on cash from foreign currency translation

-20

46

-35

-25

-0

-2

-7

-30

14

NET (DECREASE) INCREASE IN CASH

-1,064

-387

-1,981

3,315

5,862

-464

-457

-847

585

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes

-

-

-

-

-

-

-

0

0

Cash paid for interest expense

-

-

-

-

-

-

-

0

0

NONCASH INVESTING AND FINANCING ACTIVITIES:
Capital contribution

215

-

-

-

-

-

-

-

-

Issuance of warrants to placement agents

-

0

0

0

247

-

-

-

-